Perception of pneumocystis jirovecii pneumonia (PJP) prophylaxis in glioma patients receiving concurrent temozolomide and radiation– a patient and physician survey
Journal of Neuro-Oncology · 2024-09 · 169 (3) · 625-632
DOI: 10.1007/s11060-024-04764-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 06.08.2024. Verfasst von Ana-Alicia Beltran-Bless und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, University of Ottawa and the Ottawa Hospital, Ottawa, ON, K1H 8L6, Canada. Hauptthemen laut MEDLINE: Temozolomide, Glioma, Pneumonia, Pneumocystis, Antineoplastic Agents, Alkylating. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Pneumocystis jirovecii pneumonia (PJP) prophylaxis is required by provincial and national drug monographs during glioma treatment using temozolomide (TMZ) concurrently with radiation (TMZ-RT). However, real-world data suggest the potential benefits of PJP prophylaxis may not outweigh its potential harms in this population. METHODS: We conducted a single-center patient survey and a national physician survey to explore the role of PJP prophylaxis amongst glioma patients undergoing TMZ-RT. RESULTS: 23% (31/133) of physicians and 60% (44/73) of patients completed a survey. The median patient age was 42 (range 20-77); 85% (34/40) had completed adjuvant TMZ. Although only 2.4% (1/41) of patients received PJP prophylaxis, only one person (without PJP prophylaxis) was hospitalized for pneumonia. When presented with hypothetical PJP risks, 13.2% (5/38) of patients were concerned about PJP infection, while 26% (10/38) were concerned about potential side effects from prophylactic antibiotics. Most physicians (77%, 17/22) perceived the evidence for PJP prophylaxis as weak; 58% (11/19) did not routinely prescribe prophylaxis, and 73% (16/22) felt that PJP prophylaxis should be limited to patients with additional risk factors. Over 95% of physicians estimated that the incidence of PJP was < 1% in their last 5 years of practice regardless of PJP prophylaxis. For 73% (16/22) of physicians, to prescribe PJP prophylaxis, the risk of PJP infection needed to be 3-8%. CONCLUSION: The current recommendation to routinely prescribe PJP prophylaxis in patients receiving TMZ-RT in the absence of other risk factors warrants reconsideration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Medicine, University of Ottawa and the Ottawa Hospital, Ottawa, ON, K1H 8L6, Canada.
- Department of Medicine, College of Medicine, Qassim University, Qassim, 52571, Saudi Arabia.
- Department of Oncology, Western University, London, ON, Canada.
- Ottawa Hospital Research Institute, Ottawa, ON, K1Y 4E9, Canada.
- Division of Medical Oncology, Department of Medicine, University of Ottawa and the Ottawa Hospital, Ottawa, ON, K1H 8L6, Canada. teng@toh.ca.
- Ottawa Hospital Research Institute, Ottawa, ON, K1Y 4E9, Canada. teng@toh.ca.
Zitieren
APA
Beltran-Bless, A. A., Alshamsan, B., Jia, J., Lo, V., Climans, S., Nicholas, G., & Ng, T. L. (2024). Perception of pneumocystis jirovecii pneumonia (PJP) prophylaxis in glioma patients receiving concurrent temozolomide and radiation– a patient and physician survey. Journal of Neuro-Oncology, 169(3), 625-632. https://doi.org/10.1007/s11060-024-04764-6
Vancouver
Beltran-Bless AA, Alshamsan B, Jia J, Lo V, Climans S, Nicholas G, et al. Perception of pneumocystis jirovecii pneumonia (PJP) prophylaxis in glioma patients receiving concurrent temozolomide and radiation– a patient and physician survey. Journal of Neuro-Oncology. 2024;169(3):625-632. doi:10.1007/s11060-024-04764-6
BibTeX
@article{BeltranBless2024,
author = {Beltran-Bless, Ana-Alicia and Alshamsan, Bader and Jia, Jason and Lo, Victor and Climans, Seth and Nicholas, Garth and Ng, Terry L},
title = {Perception of pneumocystis jirovecii pneumonia (PJP) prophylaxis in glioma patients receiving concurrent temozolomide and radiation– a patient and physician survey},
journal = {Journal of Neuro-Oncology},
year = {2024},
volume = {169},
number = {3},
pages = {625--632},
doi = {10.1007/s11060-024-04764-6}
}
EUVIMED